Skip to main content

Antipsychotics for the treatment of Catatonia

We should evaluate all prescribed medications for their potential to induce catatonic symptoms and discontinued if possible. There is some ambiguity about the role of antipsychotics, but they generally encourage it to discontinue antipsychotic treatment in patients presenting with catatonia (46). In the presence of a catatonic state, both first and second-generation antipsychotics (SGA) may contribute to maintaining or worsening the catatonic state and increase the risk of developing NMS (51–54). During a prospective follow-up of 82 patients that had received antipsychotics at some point when catatonic, NMS developed in three cases (3.6%) (4), a substantially higher incidence than the estimated incidence of 0.07–1.8% in all antipsychotics-treated patients (55). The risk of worsening catatonia appears greater with neuroleptics and antipsychotics with higher D2-blockade and a higher potential of causing extrapyramidal side effects (56), but a worsening of catatonia and precipitation of NMS has also been reported in association with, e.g., olanzapine (57, 58).


Although it is generally accepted that neuroleptics are ineffective in catatonia (59), the role of the SGA in the treatment of catatonia is more ambiguous and based on cases mostly with schizophrenia (21). SGA has weak GABA-agonist activity and 5HT2-antagonism that could stimulate dopamine release in the prefrontal cortex and thus alleviate catatonic symptoms (11). Several authors have reported a beneficial effect of SGA, such as clozapine (60–63), olanzapine (64–66), risperidone (67–70), and quetiapine (71). In one randomized controlled trial, in 14 stuporous psychotic patients, risperidone (4–6 mg/day) was compared to ECT. ECT-treated patients showed significantly greater improvement than those receiving risperidone (72).


The use of antipsychotics in the presence of catatonia should be evaluated in any individual case. We support, however, the general notion to discontinue neuroleptics because of their inefficacy and their potential of aggravating the catatonic symptoms. Once treatment with benzodiazepines or ECT is started and catatonia improves, there may be a role for SGA to target residual psychotic symptoms such as delusions or hallucinations, especially in patients with schizophrenia (69), or as a prophylactic treatment in psychotic disorders and mood disorders. SGA with low D2 blockade (quetiapine, olanzapine) or with D2 partial agonism (aripiprazole) should be favored in these situations (54).


Patients presenting with both delirium and catatonia warrant special consideration (73, 74). Catatonia is a frequent feature of delirious mania, a severe syndrome characterized by the rapid onset of delirium, mania, and psychosis. Symptoms of catatonia and delirium overlap, complicating diagnosis. DSM states that catatonia should not be diagnosed if it occurs during a delirium. The issue is important because treatments for catatonia and delirium are different, albeit with overlap. While we typically treat delirium with (typical or atypical) antipsychotics, the emergence of catatonia may caution against the use of antipsychotics (75, 76). If we do not recognize catatonia in a delirious patient, the withdrawal or withholding of benzodiazepines sometimes thought to worsen delirium may induce catatonia or leave catatonia untreated. Further studies in delirious patients are needed to aid these treatment dilemmas (77).



Comments

Popular posts from this blog

ADVOKATE: A Mnemonic Tool for the Assessment of Eyewitness Evidence

ADVOKATE: A Mnemonic Tool for Assessment of Eyewitness Evidence A tool for assessing eyewitness  ADVOKATE is a tool designed to assess eyewitness evidence and how much it is reliable. It requires the user to respond to several statements/questions. Forensic psychologists, police or investigative officer can do it. The mnemonic ADVOKATE stands for: A = amount of time under observation (event and act) D = distance from suspect V = visibility (night-day, lighting) O = obstruction to the view of the witness K = known or seen before when and where (suspect) A = any special reason for remembering the subject T = time-lapse (how long has it been since witness saw suspect) E = error or material discrepancy between the description given first or any subsequent accounts by a witness.  Working with suspects (college.police.uk)

ICD-11 Criteria for Attention Deficit Hyperactivity Disorder (ADHD) 6A05

ICD-11 Criteria for Attention Deficit Hyperactivity Disorder (ADHD) 6A05 Attention deficit hyperactivity disorder is characterised by a persistent pattern (at least 6 months) of inattention and/or hyperactivity-impulsivity that has a direct negative impact on academic, occupational, or social functioning. There is evidence of significant inattention and/or hyperactivity-impulsivity symptoms prior to age 12, typically by early to mid-childhood, though some individuals may first come to clinical attention later. The degree of inattention and hyperactivity-impulsivity is outside the limits of normal variation expected for age and level of intellectual functioning. Inattention refers to significant difficulty in sustaining attention to tasks that do not provide a high level of stimulation or frequent rewards, distractibility and problems with organisation. Hyperactivity refers to excessive motor activity and difficulties with remaining still, most evident in structured situations that re...

ICD-11 Criteria for Depression (Recurrent Depressive Disorder) 6A71

ICD-11 Criteria for Depression (Recurrent Depressive Disorder) 6A71 Recurrent depressive disorder is characterised by a history or at least two depressive episodes separated by at least several months without significant mood disturbance. A depressive episode is characterised by a period of depressed mood or diminished interest in activities occurring most of the day, nearly every day during a period lasting at least two weeks accompanied by other symptoms such as difficulty concentrating, feelings of worthlessness or excessive or inappropriate guilt, hopelessness, recurrent thoughts of death or suicide, changes in appetite or sleep, psychomotor agitation or retardation, and reduced energy or fatigue. There have never been any prior manic, hypomanic, or mixed episodes, which would indicate the presence of a Bipolar disorder. Inclusions:                Seasonal depressive disorder Exclusions:    ...